
Global Plasma Derived Medicine Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Plasma Derived Medicine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Plasma Derived Medicine market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Plasma Derived Medicine market include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, CBPO, Shuanglin Bio, RAAS, Nanyue Bio and Hualan Bio, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Plasma Derived Medicine, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Plasma Derived Medicine, also provides the value of main regions and countries. Of the upcoming market potential for Plasma Derived Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Plasma Derived Medicine revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Plasma Derived Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Plasma Derived Medicine company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Plasma Derived Medicine Segment by Company
Yuanda Shuyang
Takeda
Weiguang Bio
Tiantan Bio
CBPO
Shuanglin Bio
RAAS
Nanyue Bio
Hualan Bio
Boya Bio
Octapharma
LFB Group
KM Biologics
Kedrion
Grifols
CSL
BPL
Biotest
Plasma Derived Medicine Segment by Type
Albumin
Immune Globulin
Coagulation Factor
Others
Plasma Derived Medicine Segment by Application
Hospital
Retail Pharmacy
Other
Plasma Derived Medicine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Plasma Derived Medicine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Plasma Derived Medicine key companies, revenue, market share, and recent developments.
3. To split the Plasma Derived Medicine breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Plasma Derived Medicine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Plasma Derived Medicine significant trends, drivers, influence factors in global and regions.
6. To analyze Plasma Derived Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma Derived Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Plasma Derived Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma Derived Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Plasma Derived Medicine industry.
Chapter 3: Detailed analysis of Plasma Derived Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Plasma Derived Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Plasma Derived Medicine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
According to APO Research, the global Plasma Derived Medicine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Plasma Derived Medicine market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Plasma Derived Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Plasma Derived Medicine market include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, CBPO, Shuanglin Bio, RAAS, Nanyue Bio and Hualan Bio, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Plasma Derived Medicine, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Plasma Derived Medicine, also provides the value of main regions and countries. Of the upcoming market potential for Plasma Derived Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Plasma Derived Medicine revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Plasma Derived Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Plasma Derived Medicine company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Plasma Derived Medicine Segment by Company
Yuanda Shuyang
Takeda
Weiguang Bio
Tiantan Bio
CBPO
Shuanglin Bio
RAAS
Nanyue Bio
Hualan Bio
Boya Bio
Octapharma
LFB Group
KM Biologics
Kedrion
Grifols
CSL
BPL
Biotest
Plasma Derived Medicine Segment by Type
Albumin
Immune Globulin
Coagulation Factor
Others
Plasma Derived Medicine Segment by Application
Hospital
Retail Pharmacy
Other
Plasma Derived Medicine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Plasma Derived Medicine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Plasma Derived Medicine key companies, revenue, market share, and recent developments.
3. To split the Plasma Derived Medicine breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Plasma Derived Medicine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Plasma Derived Medicine significant trends, drivers, influence factors in global and regions.
6. To analyze Plasma Derived Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasma Derived Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Plasma Derived Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasma Derived Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Plasma Derived Medicine industry.
Chapter 3: Detailed analysis of Plasma Derived Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Plasma Derived Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Plasma Derived Medicine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Table of Contents
204 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Plasma Derived Medicine Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Plasma Derived Medicine Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Plasma Derived Medicine Market Dynamics
- 2.1 Plasma Derived Medicine Industry Trends
- 2.2 Plasma Derived Medicine Industry Drivers
- 2.3 Plasma Derived Medicine Industry Opportunities and Challenges
- 2.4 Plasma Derived Medicine Industry Restraints
- 3 Plasma Derived Medicine Market by Company
- 3.1 Global Plasma Derived Medicine Company Revenue Ranking in 2024
- 3.2 Global Plasma Derived Medicine Revenue by Company (2020-2025)
- 3.3 Global Plasma Derived Medicine Company Ranking (2023-2025)
- 3.4 Global Plasma Derived Medicine Company Manufacturing Base and Headquarters
- 3.5 Global Plasma Derived Medicine Company Product Type and Application
- 3.6 Global Plasma Derived Medicine Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Plasma Derived Medicine Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 Plasma Derived Medicine Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Plasma Derived Medicine Market by Type
- 4.1 Plasma Derived Medicine Type Introduction
- 4.1.1 Albumin
- 4.1.2 Immune Globulin
- 4.1.3 Coagulation Factor
- 4.1.4 Others
- 4.2 Global Plasma Derived Medicine Sales Value by Type
- 4.2.1 Global Plasma Derived Medicine Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Plasma Derived Medicine Sales Value by Type (2020-2031)
- 4.2.3 Global Plasma Derived Medicine Sales Value Share by Type (2020-2031)
- 5 Plasma Derived Medicine Market by Application
- 5.1 Plasma Derived Medicine Application Introduction
- 5.1.1 Hospital
- 5.1.2 Retail Pharmacy
- 5.1.3 Other
- 5.2 Global Plasma Derived Medicine Sales Value by Application
- 5.2.1 Global Plasma Derived Medicine Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Plasma Derived Medicine Sales Value by Application (2020-2031)
- 5.2.3 Global Plasma Derived Medicine Sales Value Share by Application (2020-2031)
- 6 Plasma Derived Medicine Regional Value Analysis
- 6.1 Global Plasma Derived Medicine Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global Plasma Derived Medicine Sales Value by Region (2020-2031)
- 6.2.1 Global Plasma Derived Medicine Sales Value by Region: 2020-2025
- 6.2.2 Global Plasma Derived Medicine Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America Plasma Derived Medicine Sales Value (2020-2031)
- 6.3.2 North America Plasma Derived Medicine Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Plasma Derived Medicine Sales Value (2020-2031)
- 6.4.2 Europe Plasma Derived Medicine Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Plasma Derived Medicine Sales Value (2020-2031)
- 6.5.2 Asia-Pacific Plasma Derived Medicine Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America Plasma Derived Medicine Sales Value (2020-2031)
- 6.6.2 South America Plasma Derived Medicine Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Plasma Derived Medicine Sales Value (2020-2031)
- 6.7.2 Middle East & Africa Plasma Derived Medicine Sales Value Share by Country, 2024 VS 2031
- 7 Plasma Derived Medicine Country-level Value Analysis
- 7.1 Global Plasma Derived Medicine Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global Plasma Derived Medicine Sales Value by Country (2020-2031)
- 7.2.1 Global Plasma Derived Medicine Sales Value by Country (2020-2025)
- 7.2.2 Global Plasma Derived Medicine Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.3.2 USA Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.7.2 France Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.14.2 China Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.17.2 India Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt Plasma Derived Medicine Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt Plasma Derived Medicine Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt Plasma Derived Medicine Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Yuanda Shuyang
- 8.1.1 Yuanda Shuyang Comapny Information
- 8.1.2 Yuanda Shuyang Business Overview
- 8.1.3 Yuanda Shuyang Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.1.4 Yuanda Shuyang Plasma Derived Medicine Product Portfolio
- 8.1.5 Yuanda Shuyang Recent Developments
- 8.2 Takeda
- 8.2.1 Takeda Comapny Information
- 8.2.2 Takeda Business Overview
- 8.2.3 Takeda Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.2.4 Takeda Plasma Derived Medicine Product Portfolio
- 8.2.5 Takeda Recent Developments
- 8.3 Weiguang Bio
- 8.3.1 Weiguang Bio Comapny Information
- 8.3.2 Weiguang Bio Business Overview
- 8.3.3 Weiguang Bio Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.3.4 Weiguang Bio Plasma Derived Medicine Product Portfolio
- 8.3.5 Weiguang Bio Recent Developments
- 8.4 Tiantan Bio
- 8.4.1 Tiantan Bio Comapny Information
- 8.4.2 Tiantan Bio Business Overview
- 8.4.3 Tiantan Bio Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.4.4 Tiantan Bio Plasma Derived Medicine Product Portfolio
- 8.4.5 Tiantan Bio Recent Developments
- 8.5 CBPO
- 8.5.1 CBPO Comapny Information
- 8.5.2 CBPO Business Overview
- 8.5.3 CBPO Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.5.4 CBPO Plasma Derived Medicine Product Portfolio
- 8.5.5 CBPO Recent Developments
- 8.6 Shuanglin Bio
- 8.6.1 Shuanglin Bio Comapny Information
- 8.6.2 Shuanglin Bio Business Overview
- 8.6.3 Shuanglin Bio Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.6.4 Shuanglin Bio Plasma Derived Medicine Product Portfolio
- 8.6.5 Shuanglin Bio Recent Developments
- 8.7 RAAS
- 8.7.1 RAAS Comapny Information
- 8.7.2 RAAS Business Overview
- 8.7.3 RAAS Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.7.4 RAAS Plasma Derived Medicine Product Portfolio
- 8.7.5 RAAS Recent Developments
- 8.8 Nanyue Bio
- 8.8.1 Nanyue Bio Comapny Information
- 8.8.2 Nanyue Bio Business Overview
- 8.8.3 Nanyue Bio Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.8.4 Nanyue Bio Plasma Derived Medicine Product Portfolio
- 8.8.5 Nanyue Bio Recent Developments
- 8.9 Hualan Bio
- 8.9.1 Hualan Bio Comapny Information
- 8.9.2 Hualan Bio Business Overview
- 8.9.3 Hualan Bio Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.9.4 Hualan Bio Plasma Derived Medicine Product Portfolio
- 8.9.5 Hualan Bio Recent Developments
- 8.10 Boya Bio
- 8.10.1 Boya Bio Comapny Information
- 8.10.2 Boya Bio Business Overview
- 8.10.3 Boya Bio Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.10.4 Boya Bio Plasma Derived Medicine Product Portfolio
- 8.10.5 Boya Bio Recent Developments
- 8.11 Octapharma
- 8.11.1 Octapharma Comapny Information
- 8.11.2 Octapharma Business Overview
- 8.11.3 Octapharma Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.11.4 Octapharma Plasma Derived Medicine Product Portfolio
- 8.11.5 Octapharma Recent Developments
- 8.12 LFB Group
- 8.12.1 LFB Group Comapny Information
- 8.12.2 LFB Group Business Overview
- 8.12.3 LFB Group Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.12.4 LFB Group Plasma Derived Medicine Product Portfolio
- 8.12.5 LFB Group Recent Developments
- 8.13 KM Biologics
- 8.13.1 KM Biologics Comapny Information
- 8.13.2 KM Biologics Business Overview
- 8.13.3 KM Biologics Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.13.4 KM Biologics Plasma Derived Medicine Product Portfolio
- 8.13.5 KM Biologics Recent Developments
- 8.14 Kedrion
- 8.14.1 Kedrion Comapny Information
- 8.14.2 Kedrion Business Overview
- 8.14.3 Kedrion Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.14.4 Kedrion Plasma Derived Medicine Product Portfolio
- 8.14.5 Kedrion Recent Developments
- 8.15 Grifols
- 8.15.1 Grifols Comapny Information
- 8.15.2 Grifols Business Overview
- 8.15.3 Grifols Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.15.4 Grifols Plasma Derived Medicine Product Portfolio
- 8.15.5 Grifols Recent Developments
- 8.16 CSL
- 8.16.1 CSL Comapny Information
- 8.16.2 CSL Business Overview
- 8.16.3 CSL Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.16.4 CSL Plasma Derived Medicine Product Portfolio
- 8.16.5 CSL Recent Developments
- 8.17 BPL
- 8.17.1 BPL Comapny Information
- 8.17.2 BPL Business Overview
- 8.17.3 BPL Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.17.4 BPL Plasma Derived Medicine Product Portfolio
- 8.17.5 BPL Recent Developments
- 8.18 Biotest
- 8.18.1 Biotest Comapny Information
- 8.18.2 Biotest Business Overview
- 8.18.3 Biotest Plasma Derived Medicine Revenue and Gross Margin (2020-2025)
- 8.18.4 Biotest Plasma Derived Medicine Product Portfolio
- 8.18.5 Biotest Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.